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A B S T R A C T   
Migraine attacks can involve changes of appetite: while fasting or skipping meals are often reported triggers in 
susceptible individuals, hunger or food craving are reported in the premonitory phase. Over the last decade, 
there has been a growing interest and recognition of the importance of studying these overlapping fields of 
neuroscience, which has led to novel findings. The data suggest additional studies are needed to unravel key 
neurobiological mechanisms underlying the bidirectional interaction between migraine and appetite. Herein, we 
review information about the metabolic migraine phenotype and explore migraine therapeutic targets that have 
a strong input on appetite neuronal circuits, including the calcitonin gene-related peptide (CGRP), the pituitary 
adenylate cyclase-activating polypeptide (PACAP) and the orexins. Furthermore, we focus on potential thera-
peutic peptide targets that are involved in regulation of feeding and play a role in migraine pathophysiology, 
such as neuropeptide Y, insulin, glucagon and leptin. We then examine the orexigenic - anorexigenic circuit 
feedback loop and explore glucose metabolism disturbances. Additionally, it is proposed a different perspective 
on the most reported feeding-related trigger - skipping meals - as well as a link between contrasting feeding 
behaviors (skipping meals vs food craving). Our review aims to increase awareness of migraine through the lens 
of appetite neurobiology in order to improve our understanding of the earlier phase of migraine, encourage 
better studies and cross-disciplinary collaborations, and provide novel migraine-specific therapeutic 
opportunities.   
1. Introduction 
Diet has been implicated in migraine over decades (Dalton, 1975; 
Dalton, 1977; Dalton and Dalton, 1979; Diamond et al., 1986; Medina 
and Diamond, 1978). In the clinical setting dietary guidelines rely on 
elimination of extensive lists of food triggers to prevent migraine attacks 
in headache patients (Mahan and Raymond, 2017), offering neither a 
strong rationale nor objective data to support the advice. These triggers 
are primarily based on retrospective reports from patients and can 
include a diverse list of foods including chocolate, dairy products, eggs, 
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citrus fruits, artificial sweeteners, sweetened beverages, alcoholic bev-
erages, etc. (Fukui et al., 2008; Millichap and Yee, 2003). The fact that 
these foods/drinks have very little in common, often lead to no useful 
outcome, and with emerging clinical (Giffin et al., 2003b; Karsan et al., 
2020b; Onderwater et al., 2020) and imaging data (Karsan and Goadsby, 
2020; Maniyar et al., 2013) on the premonitory phase of migraine, led us 
to question whether appetite pathways overlap with migraine patho-
physiology (Goadsby et al., 2017; Martins-Oliveira et al., 2016; Martins- 
Oliveira et al., 2017a; Martins-Oliveira et al., 2017b) to create the illu-
sion of a trigger. Currently, investigation of the premonitory phase of the 
migraine has expanded, with several neuroimaging studies in induced- 
and spontaneous- migraine attacks in headache patients (Maniyar et al., 
2013; Schulte et al., 2015; Sprenger and Goadsby, 2010). However, 
many questions remain to formulate a better understanding of appetite 
neurobiology in migraine. 
To address gaps in understanding in these overlapping fields of 
neuroscience, this review presents the metabolic migraine phenotype, 
introduces key appetite-regulating peptides with a role in migraine 
pathophysiology, and analyzes different perspectives on feeding-related 
triggers. This narrative review is a non-systematic summation and 
analysis of available literature, with no formal guidelines. We divided 
the literature into several sections/themes, compare and contrast ideas 
and findings of multiple sources, and then interpret and critically eval-
uate it to make an overall point throughout each section of the manu-
script. We recapitulate important features of historical studies in both 
fields and aim to synthesize it by rephrasing the study’s significance 
relating it to our topic. Overall, the review blends independent, and 
apparently unrelated, ideas and findings into an original and novel 
perspective of the intersection of appetite and migraine. 
2. Appetite changes, gastrointestinal (GI) function and the 
metabolic phenotype in migraine 
Migraine is an inherited, episodic disorder involving sensory sensi-
tivity (Goadsby and Holland, 2019), whose key marker is headache, 
with certain associated features, such as nausea, photophobia and 
phonophobia (Headache Classification Committee of the International 
Headache Society (IHS), 1988), and, in one-fifth of patients, an aura 
with neurologic symptoms (Lance and Goadsby, 2005). It has been 
classically dissected into four phases that may occur in a linear 
sequential order, although in most cases show a significant overlap: the 
premonitory, aura, headache and the postdrome phase (Akerman et al., 
2011; Goadsby et al., 2002). Premonitory symptoms can include thirst 
and changes in appetite (hunger and/or food craving), as well as mood 
changes, tiredness or yawning, indicating an underlying hypothalamic 
dysfunction (Giffin et al., 2003b). Importantly, premonitory symptoms 
are more common than aura symptoms (Karsan and Goadsby, 2018), 
which suggests their understanding is important. 
Migraineurs experience attacks and report they are preceded by 
triggering factors, such as food deprivation or fasting/skipping meals 
(Dalkara and Kiliç, 2013). In one study, Martin and Seneviratne (Martin 
and Seneviratne, 1997) found that food deprivation was associated with 
headache in 58% of patients with frequent migraine or tension-type 
headache. Moreover, Blau and Cumings (Blau and Cumings, 1966) re-
ported that fasting caused headache in 50% of migraineurs and 
concluded “some patients have some of their attacks of migraine fired off 
by missing a meal, and that this is related to a low blood sugar, which 
must persist in that individual for a certain length of time to cause 
headache”. Conversely, there are many observations of food cravings 
during the premonitory phase of migraine, with researchers reporting 
that some patients would crave for sweet or highly palatable foods, for 
example chocolate (Drummond and Lance, 1984a). Studies revealed 
that around 18% of the patients report food cravings or hunger as trig-
gers of their headache (Giffin et al., 2003a; Schoonman et al., 2006), 
with no significant differences between migraine with or without aura 
(Schulte et al., 2015). 
It is still debated whether some foods, which incidentally are highly 
palatable, are actually triggers or rather that food craving is a symptom 
in the premonitory phase of migraine. Some authors attempted to 
reconcile these factors - food deprivation, hunger and food cravings, 
suggesting that “hunger arising from low blood sugar levels, for 
example, may lead to cravings for particular foods such as chocolate, on 
the one hand, and lead to headaches, on the other hand, but the head-
aches may be erroneously attributed to the food consumption rather 
than the low blood sugar levels” (Martin and Seneviratne, 1997). 
Nevertheless, studies fail to discriminate if susceptible migraineurs 
specifically reporting premonitory food cravings experienced food 
deprivation or skipped meal hours before food craving. Remarkably, in 
patients who report they have food triggers, 81% report hunger or 
cravings during the premonitory phase of a nitroglycerin-induced attack 
(Karsan et al., 2020b). 
Regarding body weight, studies report weight change is a side-effect 
commonly associated with medications used for migraine prophylaxis, 
although studies do not report appetite changes (Taylor, 2008; Young, 
2008). It is suggested these medications impact appetite and feeding 
behavior probably through hypothalamic pathways, for instance leptin 
resistance (Berilgen et al., 2005). The exact mechanism is currently 
unknown, and it is also possible these medications interfere with basal 
metabolic rate, which is another physiological way of impacting body 
weight. Prophylactic treatment is therefore a factor that should be 
considered when interpreting these studies. 
The biopsychosocial model of feeding behavior is also relevant in 
migraine pathophysiology. On one hand, patients with migraine are at 
increased risk for major depression and anxiety when compared to 
subjects without migraine (Dresler et al., 2019), which are known to 
cause appetite changes. On the other hand, some premonitory symptoms 
related to sensory processing may also impact feeding behavior, for 
instance osmophobia. Appetite regulation involves integration of 
gastrointestinal physiology, neurobiology as well as cognitive and 
behavioral sciences. The sense of smell plays a role in the homeostatic 
and hedonic aspects of feeding and contributes to building and main-
taining well-being through supporting nutrition and social relationships, 
yet scientific evidence is scarce to confirm it affects actual food ingestion 
and underlying mechanisms (Boesveldt and Parma, 2021; Fine and 
Riera, 2019). What is understood is disturbances of olfaction can lead to 
weight loss driven by psychological factors (e.g. depression) (Fine and 
Riera, 2019). Although there is no human data correlating osmophobia 
and appetite changes in the premonitory phase of the migraine attack, it 
is possible that patients feel less inclined to eat certain foods during this 
phase. 
Migraine has been associated with gastrointestinal (GI) dysfunction. 
For instance, GI complaints increase with increasing headache fre-
quency, migraines are often accompanied by various GI symptoms, and 
patients with migraine are more prone to GI disorders (Aamodt et al., 
2008; Lee et al., 2017). Given this association, it has been suggested the 
gut microbiota might play a pivotal role in migraine through the gut–-
brain axis (Gazerani, 2021). In addition, animal studies have shown that 
appetite-regulating hormones are under the influence of the gut 
microbiota (Holzer, 2016), though a causal association in migraine pa-
tients is lacking. Diet is perhaps one of the greatest factors influencing 
microbiota composition and many conditions wherein food intake 
behavior is dysregulated are associated with an altered gut microbiota, 
that might affect the ability to sense and taste nutrients (Cryan et al., 
2019). Interventions with probiotics help improve gut microbiota and 
several probiotic trials in migraine patients have been published (Arzani 
et al., 2020). Nonetheless, a systematic review (Naghibi et al., 2019) 
concluded that there is a clear lack of consistency in the results and a 
recent meta-analysis (Parohan et al., 2020) confirmed probiotic sup-
plementation had no significant effect on the frequency and severity of 
episodic migraine attacks. 
Furthermore, a correlation between migraine and abnormal glucose 
metabolism has been suggested and clinical studies have shown some 
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evidence of an altered insulin and glucose metabolism in migraineurs. 
Two clinical studies consistently show higher insulin levels in migrai-
neurs than in controls (Cavestro et al., 2007; Rainero et al., 2005) 
implying that insulin resistance is present in migraineurs. Interestingly, 
Critchley and Ferguson (Critchley and Ferguson, 1933) stated that 
“migraine attacks induced by hunger or fasting were unlikely to be 
directly related to absolute blood glucose levels and nor does it seem 
likely that such attacks were related to the rapidity of the fall in venous 
blood sugar”. Perhaps what these studies demonstrate most is a likely 
adaptive response to the shift of glucose metabolism in migraine patients 
(this will be further discussed in 5. Glucose metabolism disturbances in 
migraine: the role of appetite-regulating peptides and 6. Fasting and/or 
skipping meals in migraine: voluntary or loss of appetite?). 
3. Appetite-regulating peptides and relevance to migraine 
pathophysiology 
Migraine pathophysiology is thought to involve activation and 
sensitization of trigeminovascular nociceptive pathways that innervate 
the cranial vasculature, and activation of brainstem nuclei (Akerman 
et al., 2013). The trigeminovascular system relevant to headache in-
cludes the pseudo-unipolar trigeminal ganglion neurons and their pro-
jections to the trigeminal nucleus caudalis (TNC) and C1 and C2 regions 
in the medullary and cervical spinal cord – the trigeminocervical com-
plex (TCC), and its peripheral afferent projections mainly from the 
ophthalmic division (V1) of the trigeminal nerve to the cranial blood 
vessels and other cranial structures, including the dura mater (Akerman 
et al., 2011). Stimulation of the dural vasculature produces neuronal 
activation in the TNC, and is likely painful in humans (Feindel et al., 
1960; Penfield and McNaughton, 1940) because the vascular structures 
of the dura mater, including the superior sagittal sinus (SSS) and middle 
meningeal artery (MMA), are richly innervated by a plexus of largely 
unmyelinated sensory nerve fibers from the ophthalmic division of the 
trigeminal ganglion (Akerman et al., 2013). Preclinical models have 
taken advantage of this primarily nociceptive pathway, the dural tri-
geminovascular nociception, to examine aspects of head pain thought to 
be involved in migraine (Bergerot et al., 2006; Martins-Oliveira et al., 
2016; Martins-Oliveira et al., 2017a). 
Regarding appetite, metabolism and feeding behavior, several brain 
structures are involved as a synchronized network (Palmiter, 2018; Sohn 
et al., 2013; Yeo and Heisler, 2012). The hypothalamus is a major center 
of convergence and integration of several nutrient-related signals (an 
integrated view is presented in Fig. 1) and, thus, hypothalamic neurons 
are thought to promote the homeostasis of physiological systems 
involved in synchronization of circadian rhythms, salt balance, appetite 
and energy expenditure, thirst and water balance, among other func-
tions (Rolls et al., 2010). Neuroimaging studies in the premonitory phase 
have demonstrated activation of the hypothalamus and a region 
consistent with the ventral tegmental area (VTA) (Maniyar et al., 2014), 
while a somewhat different hypothalamic site is activated during the 
attack (Denuelle et al., 2007). This is in agreement with earlier animal 
studies (Bartsch et al., 2004b; Benjamin et al., 2004a; Burstein et al., 
1987; Malick et al., 2000), establishing the hypothalamus as an impor-
tant brain area in migraine pathophysiology (Charbit et al., 2009) 
(Benjamin et al., 2004b; Malick and Burstein, 1998). For instance, 
stimulation of the dura mater in the rat produces Fos expression in the 
ventromedial (VMH), paraventricular (PVN) and dorsomedial hypo-
thalamic nuclei (DMH), resulting in suppression of appetite and in in-
creases in arterial blood pressure (Malick et al., 2001); and stimulation 
of the SSS in the cat results in hypothalamic activation with up- 
regulation of Fos protein-like immunoreactivity in the supra-optic and 
posterior hypothalamic nucleus (Benjamin et al., 2004b). Therefore, 
experimental data suggest that hypothalamic structures can directly 
regulate trigeminovascular nociceptive afferent traffic. In addition, the 
hypothalamus is in a strategic position to receive neuronal inputs from 
other appetite-regulating structures to impact on some of the 
Fig. 1. Feeding neuronal circuits that interact with 
the trigeminocervical complex (TCC) and other brain 
stem nuclei involved in pain modulation. Peripheral 
circulating hormones produced by the adipose tissue 
and pancreas interact with hypothalamic arcuate 
(ARC) neurons containing neuropeptide Y (NPY)/ 
agouti-related peptide and proopiomelanocortin 
/cocaine and amphetamine- regulated transcript to 
regulate food intake and energy expenditure. These 
circulating hormones also influence the midbrain 
ventral tegmental area (VTA) and the TCC in the 
medulla. The circuitry of energy homeostasis com-
prises ARC neurons that transmit information to spe-
cific nuclei within the hypothalamus, including the 
paraventricular nucleus (PVN) and the lateral hypo-
thalamus (LH). The ventral tegmental area (VTA) re-
ceives information from ARC neurons and comprises 
the dopaminergic mesolimbic pathway (nucleus 
accumbens (NAc)) involved in processing hedonic 
feeding, i.e., motivation to ingest highly palatable 
food. These nuclei may play a putative role in 
migraine pathophysiology through their descending 
projections to brain stem nuclei known to be involved 
in the modulation of headache-related pain process-
ing. These include PVN direct projections to the TCC 
and indirect projections to the periaqueductal grey 
(PAG) and parabrachial nucleus (PBN). Moreover, 
indirect communication through VTA projections to 
the PAG, PBN, the locus coeruleus (LC), and the nu-
cleus tractus solitarius (NTS) might also modulate TCC nociceptive activity. Of note, the TCC contains transmembrane receptors for leptin (ObRb) and insulin (InsR), 
as well as G-protein couple receptors for NPY (NPY Y1, Y2, Y5), glucagon (GLR), PACAP (PAC1, VPAC1 and VPAC2), CGRP (heterodimer composed of CLR, calcitonin- 
like receptor/ RAMP1, receptor activity-modifying protein) and orexins (OX1R, OX2R). Given that altered feeding affects neuronal processing in these appetite- 
regulating structures, it is likely that their physiological control of transmission of nociceptive inputs to the trigeminovascular system will be disturbed. This 
could lead to abnormal activation of the trigeminovascular system and altered perception of craniofacial pain.   
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premonitory symptoms. It is the case of the VTA, a major midbrain 
structure, we have recently shown is able to modulate trigeminovascular 
neuronal firing in response to nociceptive vascular electrical and facial 
mechanical stimulation, impacting glucose metabolism (Martins-Oli-
veira et al., 2017b). Specific appetite-related peptides that are known to 
act within the hypothalamus and the VTA will be discussed in detail 
below. 
3.1. Calcitonin gene-related peptide 
Calcitonin gene-related peptide (CGRP) is a 37-amino acid neuro-
peptide produced by alternative splicing of the calcitonin gene (Amara 
et al., 1982; Rosenfeld et al., 1983). Anatomical studies revealed that 
CGRP is widely distributed in the CNS including in the hypothalamus, 
thalamus, striatum, amygdala, brain stem, and the TCC (Hökfelt et al., 
1992; van Rossum et al., 1997; Yasui et al., 1991). In addition, CGRP is 
highly expressed in the sensory trigeminal ganglion, including its fiber 
projections to cerebral and dural vasculature and to the spinal cord 
(Edvinsson et al., 1998; Eftekhari et al., 2010; Tajti et al., 1999). 
Based on molecular cloning studies, CGRP acts at one receptor 
clearly: the canonical CGRP-receptor complex, made up of a G protein- 
coupled receptor consisting of a seven transmembrane spanning protein 
(calcitonin receptor-like receptor; CLR) and a single transmembrane 
receptor modifying protein (RAMP) 1 (Aiyar et al., 1996; McLatchie 
et al., 1998); and may act at another, the non-canonical amylin receptor 
(AMY1) that consists of the calcitonin receptor (CTR) and RAMP1 (Hay 
et al., 2015). Recently, it has been shown that CGRP activates this re-
ceptor in the rat and human sensory trigeminal system (Walker et al., 
2015). Moreover, functional CGRP receptors have been identified in the 
trigeminal ganglia, brain stem, hypothalamus, thalamus, amygdala, 
cerebellum, and cortex (Edvinsson et al., 2011; Eftekhari et al., 2010; 
Lennerz et al., 2008; Oliver et al., 2002; Summ et al., 2010; Warfvinge 
and Edvinsson, 2017). Specifically, a study in primates, using antagonist 
antibodies against CGRP, demonstrated binding to human vascular 
smooth muscle cells (VSMCs) of dural meningeal arteries and neurons in 
the trigeminal ganglion, and in monkeys in the dura mater vascular 
smooth muscle cells, in neurons and satellite glial cells in the trigeminal 
ganglion, and in neurons in the spinal trigeminal nucleus caudalis 
(Miller et al., 2016). Interestingly, in the TCC, CGRP receptors seem to 
colocalize with CGRP in terminals of primary afferents but not ascending 
fibers (Lennerz et al., 2008). 
Moreover, CGRP has potent vasodilator effects (Kurosawa et al., 
1995; Williamson et al., 1997) and is known to trigger attacks when 
given to migraine sufferers (Lassen et al., 2002). Clinical studies have 
shown that CGRP is released during spontaneous (Goadsby et al., 1990) 
or triggered attacks (Gallai et al., 1995), which can be inhibited by 
triptan treatment (Goadsby and Edvinsson, 1993). Regarding non- 
headache features, RAMP1 is critical for the transport and cell surface 
expression of the CGRP receptor complex (McLatchie et al., 1998), and 
its overexpression results in migraine-like phenotypes such as light 
aversion and allodynia (Kaiser et al., 2012; Recober et al., 2009; Russo 
et al., 2009). In fact, mice with a gain-of-function mutation of CGRP 
receptor exhibit light aversion behavior when they receive a CGRP in-
jection (Kaiser et al., 2012). Other animal studies report that local 
administration of CGRP facilitates TCC nociceptive neurons, while 
CGRP antagonism inhibited neuronal responses (Storer et al., 2004). In 
the brain, CGRP delivery into the ventrolateral PAG facilitates trigemi-
novascular processing via descending modulatory mechanisms (Pozo- 
Rosich et al., 2015), while CGRP antagonist delivery into the thalamus 
inhibited both nociceptive signaling and spontaneous background ac-
tivity (Summ et al., 2010). Consistent with this view, CGRP-induced 
spontaneous facial grimace pain was completely blocked by pre-
administration of a monoclonal anti-CGRP-blocking antibody (Rea 
et al., 2018). 
For decades, endogenous CGRP has been shown to be a key regulator 
of metabolism and energy homeostasis in vivo. In normal weight 
humans, a high-fat meal caused a sustained increase of plasma CGRP 
concentrations, whereas no change of CGRP was observed after an 
isocaloric high-carbohydrate meal (Zelissen et al., 1991). Moreover, 
plasma CGRP concentration was increased in obese women compared to 
normal-weight controls and significant weight reduction (but still obese) 
did not result in a decrease of these levels. (Zelissen et al., 1991). In 
animals, peripheral and central administration of CGRP acutely 
decreased food intake (Krahn et al., 1984; Morley et al., 1996; Sun et al., 
2010; Tannenbaum and Goltzman, 1985) and peripheral treatment 
reduced plasmatic glucagon and leptin levels (Sanford et al., 2019). 
The CGRP key role in feeding behavior is mediated by the para-
brachial nucleus (PBN) (Palmiter, 2018). Using genetically encoded 
tools, it has been demonstrated that CGRP neurons in the PBN 
(CGRPPBN) control meal termination since functional inactivation of 
these neurons increases meal size and duration, but has no effect on total 
food intake over time (Campos et al., 2016). Supporting the overall 
anorexigenic CGRP role, stimulation of CGRPPBN neurons rapidly and 
reversibly reduces food intake (Campos et al., 2016; Carter et al., 2013). 
Furthermore, there is an interaction between the PBN and the hypo-
thalamus that mediates food intake during appetite suppressing condi-
tions. For instance, stimulation of agouti-related peptide (AgRP) 
neurons ameliorated appetite suppression caused by chemogenetic 
stimulation of CGRPPBN neurons (Essner et al., 2017). Consistent with 
these data, noxious dural stimulation in an animal model of intracranial 
headache-like pain increased Fos-positive neurons in the PBN and the 
ventromedial hypothalamus (VMH) and induced a transient suppression 
of food intake (Malick and Burstein, 2001). These observations suggest 
that it is likely that CGRPPBN neurons mediated this anorexigenic effect. 
Furthermore, metabolic experiments suggest that CGRP may impair 
insulin secretion and action. More precisely, CGRP has been shown to 
inhibit insulin secretion in vitro (Pettersson et al., 1986) and inhibit the 
ability of insulin to stimulate glucose incorporation into skeletal muscle 
glycogen at physiological insulin concentrations in an isolated rat soleus 
muscle preparation (Leighton and Cooper, 1988). In conscious animals, 
CGRP induces insulin resistance by decreasing glucose uptake and 
increasing hepatic glucose production (Choi et al., 1991). In hyper-
insulinemic glucose-clamp studies in rats infused with both insulin and 
CGRP, a marked state of in vivo insulin resistance was induced and this 
effect was rapidly reversible on CGRP withdrawal (Molina et al., 1990). 
Moreover, CGRP regulates core body temperature and energy expendi-
ture, and CGRP knockout mice present better glucose tolerance and 
insulin sensitivity, than wild-type mice (Liu et al., 2017). Consistent 
with this view, it is possible that CGRP release contributes to altered 
glucose metabolism observed in migraine patients (Bernecker et al., 
2010; Cavestro et al., 2007; Fava et al., 2013; Rainero et al., 2005; Siva 
et al., 2017). 
While most acute symptomatic treatments for migraine have the 
potential to worsen migraine with frequent use (Diener et al., 2016), 
antagonism of the CGRP pathway is effective both acutely and chroni-
cally for migraine prevention (Edvinsson et al., 2018). The development 
of monoclonal antibodies antagonizing the CGRP pathway represents a 
novel approach to prevention: the very anticipated mechanism-specific 
migraine-targeted therapy. Four monoclonal antibodies are currently 
either in regulatory review or on the market for migraine prevention: 
three against CGRP itself - galcanezumab, eptinezumab, and fremane-
zumab, and one against the canonical CGRP receptor – erenumab 
(Goadsby, 2019). Although no treatment-related serious adverse events 
were reported, and adverse events were reported in a similar proportion 
of patients in the placebo and treatment groups (Tso and Goadsby, 2017; 
Zhu et al., 2018), the long-term safety is entirely unknown at this time, 
especially in terms of appetite, body weight or glucose metabolism. 
3.2. Pituitary adenylate cyclase activating polypeptide 
The pituitary adenylate cyclase activating polypeptide (PACAP) is a 
peptide first isolated from ovine hypothalamus and so named because it 
M. Martins-Oliveira et al.                                                                                                                                                                                                                     
Brain Research 1770 (2021) 147629
5
stimulates the accumulation of intracellular and extracellular cAMP in 
monolayer cultures of rat anterior pituitary cells. It is present in two 
bioactive, amidated forms, a 27- or 38-amino acid neuropeptide, and 
shows 68% sequence homology with vasoactive intestinal peptide (VIP), 
belonging to the VIP/glucagon/secretin family (Gottschall et al., 1990; 
Miyata et al., 1989; Sherwood et al., 2000). PACAP exerts its biological 
action by binding to three G protein-coupled receptors subtypes, PAC1, 
VPAC1 and VPAC2. Anatomical studies show PACAP is widespread 
throughout the CNS and peripheral tissue and binding sites include the 
TCC, spinal cord, trigeminal ganglia, sphenopalatine ganglia and CNS 
structures such as the thalamus, hypothalamus, and brain stem (Csati 
et al., 2012; Eftekhari et al., 2015; Gottschall et al., 1990; Joo et al., 
2004; Masuo et al., 1992; Uddman et al., 2002b). 
In migraineurs, PACAP induces migraine-like headaches when 
administered intravenously (Schytz et al., 2009) and systemic PACAP38 
concentrations are significantly altered depending on the migraine 
phase (Tuka et al., 2013; Zagami et al., 2014). In animal studies, 
PACAP38 administered intravenously induces delayed sensitization of 
central trigeminovascular neurons (Akerman and Goadsby, 2015), 
which translates to delayed migraine-like headaches in 50% of migraine 
patients without aura (Schytz et al., 2009). Furthermore, PACAP has 
also been linked to sensitization and light aversion as mice lacking 
PACAP do not develop light aversion or trigeminal sensitization after 
nitroglycerin-induced light aversion (Markovics et al., 2012), with likely 
implications for migraine photophobia. More specifically, central PAC1 
receptor is considered to be an important target as intravenous admin-
istration of a PAC1 receptor antagonist inhibited the peripheral menin-
geal vasodilatory effects of dural trigeminovascular nociception, 
whereas central (i.c.v.) administration of the PAC1 receptor antagonist 
inhibited dural nociceptive trigeminovascular activation (Akerman and 
Goadsby, 2015). While PACAP38 infusion in the PVN increases TCC 
spontaneous activity (Robert et al., 2013), recent work from our labo-
ratory has shown that, when microinjected into the VTA, PACAP38 in-
hibits spontaneous and noxious TCC neuronal responses (Martins- 
Oliveira et al., 2017b). These data indicate that there are still funda-
mental discoveries about the role of PACAP in nociceptive processing to 
be made such as examining the functional role of different PACAP re-
ceptors in specific brain areas. Meanwhile, PAC1 receptor antibodies 
have been successfully used in migraine pre-clinical studies (Hoffmann 
et al., 2017). A phase-II study of a PAC1 antibody has been reported in 
abstract form to be negative, so that the VPAC receptors should be re- 
considered. 
Regarding a physiological role in energy balance, PACAP is involved 
in food intake control. Brain delivery of PACAP reduces food intake 
when injected i.c.v. (Morley et al., 1992; Mounien et al., 2009) or into 
the hypothalamic PeF (Chance et al., 1995), the PVN or the VMH 
(Hurley et al., 2016; Resch et al., 2011; Resch et al., 2013; Resch et al., 
2014). In the hypothalamic arcuate nucleus (ARC), approximately 50% 
of proopiomelanocortin (POMC) neurons express both of PAC1 and 
VPAC2 receptors (Mounien et al., 2006) and consecutive in vitro studies 
showed that exogenous PACAP increased POMC mRNA expression, an 
effect further blocked by PACAP antagonist, which led scientists to 
suggest that PACAP regulation of feeding behavior is mediated, in part, 
by ARC POMC neurons. Moreover, when injected peripherally, PACAP 
reduces food intake through the PAC1 receptor (Vu et al., 2015). On a 
related note, PACAP is also involved in endocrine regulation as PACAP is 
synthesized and released by pancreatic β-cells and exerts several meta-
bolic actions, such as stimulation of insulin production and release, and 
increase of insulin-induced glucose uptake in adipocytes, thereby 
improving glucose tolerance (Nakata et al., 1999; Nakata and Yada, 
2007; Yada et al., 1994). 
Interestingly, recent work emphasizes the role of PACAP in hedonic 
feeding showing PACAP administration into specific subregions of the 
nucleus accumbens (NAc), part of the mesolimbic reward pathway, 
attenuated palatable food consumption in satiated rats, i.e., without 
altering homeostatic feeding (Hurley et al., 2018). A few studies 
highlight a putative interaction between the NAc and trigeminal pain, 
where CGRP elicits NAc dopamine release in a model of cephalic pain, 
an effect blocked by sumatriptan (De Felice et al., 2013); and stimulation 
of NAc inhibits nociceptive trigeminal nucleus caudalis neurons in a 
model of orofacial pain (Barceló et al., 2012). Furthermore, migraine 
patients showed altered resting-state functional connectivity between 
NAc and other brain structures (Yuan et al., 2013). Given that suscep-
tible migraine patients experience food cravings it is key to determine 
whether this is mediated by dysfunctional PACAP activity in discrete 
reward pathway regions, like the NAc. 
Perhaps the most important lesson from these studies is that while it 
is clear that PACAP plays a role in migraine pathophysiology, it is un-
known whether PACAP is involved in appetite changes as well as dis-
turbances of glucose metabolism in migraine patients. Our studies on the 
interaction of glucose metabolism and trigeminovascular activation 
(Martins-Oliveira et al., 2017a; Martins-Oliveira et al., 2017b) offer a 
path to investigate PACAP-mediated mechanisms and the metabolic 
profile of patients involved in clinical studies making use of PACAP to 
induce migraine-like headache. 
3.3. The orexinergic system 
Orexin A and B are two hypothalamic neuropeptides that bind to two 
G-protein coupled receptors, termed OX1R and OX2R, which are 64% 
homologous (Sakurai et al., 1998). The rat and human versions of OX1R 
and OX2R demonstrate a 94% and 95% homology, respectively, sug-
gesting a high level of conservation across mammalian species. Orexin A 
has equal affinity for both OX1R and OX2R, while orexin B demonstrates 
a 10-fold higher affinity for OX2R than OX1R (Sakurai et al., 1998). 
Hypothalamic orexin neurons project throughout the CNS, including the 
dorsolateral pons, the VTA, the PAG, as well as to the TNC and the 
thalamus (Hervieu et al., 2001). These structures have each been 
implicated in the pathophysiology of migraine by anatomical and 
physiological studies (Goadsby et al., 2009) as well as by functional 
brain imaging (Sprenger and Goadsby, 2010). In animal studies, there is 
an orexinergic modulation of the trigeminovascular system (Bartsch 
et al., 2004a; Hoffmann et al., 2015; Holland et al., 2006). For example, 
intravenous orexin A and B has shown that OX1R activation can inhibit 
nociceptive trigeminovascular processing in the trigeminocervical 
complex of the rat (Holland et al., 2006). 
Furthermore, orexin A and B are closely related to the hypothalamic 
control of feeding and body weight. These neuropeptides were shown to 
stimulate food intake when injected into the brain ventricle and hypo-
thalamic ARC (Haynes et al., 1999; Muroya et al., 2004; Sakurai et al., 
1998). While orexin B has been reported to stimulate feeding, this effect 
is much less reliably obtained than the response to orexin-A, and this 
might reflect the greater importance of the OX1R in orexin-induced 
hyperphagia or the more rapid in vivo clearance of orexin B (Smart 
et al., 2001). Studies have shown that metabolic challenges, such as 
fasting and hypoglycemia, increase orexin concentrations in the hypo-
thalamus (Cai et al., 1999; Cai et al., 2001; Karteris et al., 2005; Sakurai 
et al., 1998) in a region-specific manner as levels of OX1R mRNA were 
significantly increased in the VMH and the medial division of amygdala 
and levels of OX2R mRNA were only increased in the ARC (Lu et al., 
2000). 
In addition, systemic glucose levels seem to influence orexinergic 
activity since orexin cells are stimulated by low glucose levels and 
physiological elevations of glucose levels suppress both spontaneous and 
evoked firing in in vitro electrophysiological studies (Burdakov et al., 
2005). Of note, orexin-containing neurons show Fos-like immunoreac-
tivity in insulin-induced acute hypoglycemia (Moriguchi et al., 1999) 
and other studies reported that fasting (Sakurai et al., 1998) and insulin- 
induced hypoglycemia (Cai et al., 1999; Cai et al., 2001; Griffond et al., 
1999) increased prepro-orexin mRNA in the rat lateral hypothalamus 
(LH), whereas leptin (discussed in detail below) had the converse effect 
(López et al., 2000). These studies suggest that orexinergic mechanisms 
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might be relevant to address the mechanisms of action by which fasting/ 
skipping meals, and therefore acute hypoglycemia, may trigger migraine 
– or be perceived as a trigger – in susceptible individuals. 
3.4. Neuropeptide Y 
Neuropeptide Y (NPY) is a peptide hormone that acts on six G-pro-
tein coupled receptor subtypes (Y1-6) (Yulyaningsih et al., 2011) and is 
present in central and peripheral nervous systems, abundantly expressed 
in the basal ganglia, limbic system and the hypothalamus (Adrian et al., 
1983). 
NPY is highly synthesized in the ARC (Bai et al., 1985) and released 
in sites including the PVN and LH (Broberger et al., 1998; Stanley et al., 
1993), making it one of the most potent appetite-stimulating peptide. 
The perifornical area of the hypothalamus (PeF), at the level of the 
caudal PVN, is the most sensitive hypothalamic site for NPY-induced 
eating (Stanley et al., 1993) and i.c.v. administration of NPY (Clark 
et al., 1984; Kalra et al., 1991) or by direct microinjection into the PVN 
(Stanley and Leibowitz, 1985) stimulates food intake. Given that the 
PVN projects directly and modulates neuronal firing in the TCC (Robert 
et al., 2013), it is possible that the PVN mediates appetite changes in 
migraine. 
Furthermore, NPY secretion is regulated by peripheral signals, 
including the anorexigenic peptide leptin – which exerts inhibitory ef-
fect at medial hypothalamic ARC–NPY neurons (Stephens et al., 1995; 
Wang et al., 2008); and the orexigenic peptide orexin A – which acti-
vates NPY-containing neurons in the ARC (Yamanaka et al., 2000). It is 
thus possible that the hypothalamic ARC might mediate a part of 
migraine phenotype since ARC fibers establish putative contacts with 
major pain modulation brainstem regions, such as the periaqueductal 
gray (PAG), dorsal raphe nucleus, nucleus raphe magnus, locus coeru-
leus (LC), and the nucleus tractus solitaries (NTS) (Sim and Joseph, 
1991). Additionally, NPY Y1 receptor-deficient mice showed increased 
acute nociception (Kuphal et al., 2008) and intra-ARC administration of 
NPY showed that NPY and NPY Y1 receptor activation exerts anti-
nociceptive effects in intact rats and in rats with inflammation (Li et al., 
2005). 
In line with these results, other studies have shown an association 
between NPY mechanisms and migraine pathophysiology. One study 
reported episodic migraineurs had lower peripheral levels of NPY during 
fasting, compared with healthy controls, and these levels increased with 
amitriptyline and flunarizine preventive treatment (Caproni et al., 
2011), whereas another study found fasting NPY levels were higher in 
migraine patients than controls (Siva et al., 2017). These differences on 
baseline NPY levels might be due to different vein blood collection or 
period of attack free days. Additionally, a study examining over 1180 
genes reported NPY expression is downregulated by CSD (Choudhuri 
et al., 2002), the neurophysiological correlate of the migraine aura in 
humans (Moskowitz et al., 1993). Because NPY Y1, Y2 and Y5 receptors 
are present in the trigeminovascular system (Parker and Herzog, 1999; 
Uddman et al., 2002a), one would expect NPY to have a fundamental 
role modulating trigeminovascular pathways. In preclinical models, 
NPY is known to inhibit neurogenic dural vasodilation (Williamson, 
2000) or plasma protein extravasation (Yu and Moskowitz, 1996) via 
NPY Y1 and NPY Y2 receptors, respectively. Moreover, we have shown 
NPY inhibited trigeminovascular neuronal firing in a dose-dependent 
manner and this effect was mediated by the NPY Y1 receptor (Martins- 
Oliveira et al., 2016). These studies might reckon a protective mecha-
nism by NPY: since NPY is antinociceptive in pain and migraine animal 
models, there might be an increased demand for NPY in patients with 
frequent headache attacks, e.g. chronic migraine. 
Importantly, fasting or food deprivation, reported by some patients 
to be a migraine trigger, is known to interfere with NPY pathways. While 
hypothalamic ARC NPY mRNA expression is up-regulated by fasting 
(White and Kershaw, 1990), food deprivation markedly increased NPY 
release in the PVN both in vivo (Kalra et al., 1991) and in vitro (Dube 
et al., 1992). In addition, fasting and food restriction augmented NPY Y1 
receptor mRNA in the hypothalamus (Xu et al., 1998). Because AgRP 
neurons expressing NPY in the ARC are reciprocally innervated by 
orexin LH neurons (Broberger et al., 1998; Elias et al., 1998), it is 
possible that hypothalamic activation seen in imaging studies during 
migraine could interfere with orexinergic as well as ARC NPY neuronal 
activity. Of note, orexins and NPY functionally co-operate resulting in an 
enhanced feeding behavior (Muroya et al., 2004). Given the potential 
interactions of orexinergic hypothalamic neurons, NPY system and the 
trigeminovascular system, understanding the anatomical pharmacology 
of these potential modulatory systems is essential to perceive feeding 
mechanisms in migraine. 
3.5. Insulin 
Insulin is a hormone secreted by the beta (β) cells of the pancreatic 
islets of Langerhans and maintains normal blood glucose levels by 
facilitating cellular glucose uptake, regulating carbohydrate, lipid and 
protein metabolism (Wilcox, 2005). Of note, insulin activity is disrupted 
by CGRP in vivo and in vitro (Choi et al., 1991; Leighton and Cooper, 
1988; Liu et al., 2017; Molina et al., 1990; Pettersson et al., 1986) and 
insulin resistance is believed to be involved in the pathogenesis of 
obesity (Goossens, 2008; Samuel and Shulman, 2012). Interestingly, 
clinical studies report higher insulin levels in migraine patients, 
comparing to controls (Cavestro et al., 2007; Rainero et al., 2005). 
Moreover, a significant association between a polymorphism of 5 single 
nucleotides of the gene encoding for insulin receptors has been 
demonstrated in migraineurs (McCarthy et al., 2001) suggesting 
migraine might be more likely in susceptible persons when there is low 
insulin receptor activation (McCarthy et al., 2001). These findings may 
highlight a less understood interaction between insulin, CGRP and 
obesity. Given that a significant prevalence of insulin resistance was 
observed in chronic migraine patients (Fava et al., 2013; Siva et al., 
2017), and obesity is associated with migraine progression from an 
episodic into a chronic form (Bigal and Lipton, 2006; Bigal and Lipton, 
2008; Bigal and Rapoport, 2012), insulin dysfunction might be the 
common factor for disturbed metabolism in migraine through CGRP 
mechanisms. 
One way of mimicking the metabolic effects of fasting is to induce 
hypoglycemia via insulin, resulting in significant activation of the PVN 
and extra-hypothalamic areas such as the LC, dorsal motor nucleus of 
the vagus, and NTS (Morilak et al., 1987; Yuan and Yang, 2002). These 
data are relevant because some of these areas send neuronal projections 
to the TCC and we have recently shown that insulin administration 
directly modulates TCC neuronal firing (Martins-Oliveira et al., 2017a). 
In addition, insulin-induced hypoglycemia activates orexinergic neurons 
(Tkacs et al., 2007), which are likely to be involved in migraine path-
ophysiology (Hoffmann et al., 2015; Holland et al., 2006). 
Another factor closely related to migraine is sleep deprivation. The 
regulation of sleep, particularly within the hypothalamus, is strongly 
linked to the regulation of feeding processes, and the interaction of both 
of these homeostatic mechanisms is likely involved in migraine patho-
physiology. Both sleep and feeding rhythms are synchronized to the 
environmental 24-h cycle mainly by light–dark information perceived 
by the eyes, and regulated within the hypothalamus. Generation of these 
rhythms occurs in the master circadian clock, the suprachiasmatic nu-
cleus (SCN) of the anterior hypothalamus (Davidson et al., 2008; 
Yamazaki et al., 2000). The SCN output is crucial for synchronization of 
many metabolic and endocrine factors, such as glucose (Cailotto et al., 
2005; La Fleur et al., 1999; Ruiter et al., 2003) and leptin (Kalsbeek 
et al., 2001). Indeed, sleep deprivation induces an increase in glucose 
and insulin plasmatic levels (Reynolds et al., 2012) and lower glucose 
tolerance in humans (Spiegel et al., 1999). Additionally, sleep debt has 
been shown to have a harmful impact on carbohydrate metabolism and 
endocrine function (Spiegel et al., 1999). Thus, it is not surprising that 
impaired insulin signaling pathways may have an effect on migraine 
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pathophysiology through sleep neurobiology disruption along with 
disturbed homeostatic glucose metabolism. 
3.6. Glucagon 
Glucagon is a polypeptide secreted from pancreatic alpha (α) cells 
(Lok et al., 1994) during meals and is involved in the production of 
postprandial satiety (Geary and Smith, 1982; Geary, 1990). In addition, 
peripheral glucagon activates hepatic glucagon receptors to increase 
hepatic glucose production (HGP), an effect that is transient (Mighiu 
et al., 2013). Systemic glucagon crosses the blood–brain barrier (Lorén 
et al., 1979) and acts within the hypothalamus. In the LH, glucagon 
inhibits glucose-sensitive neuronal activity, thus contributing to the 
control of metabolism and meal termination (Inokuchi et al., 1986). 
Glucagon receptor immunoreactivity is also detected in hypothalamic 
ARC, colocalized with AgRP neurons (Hoosein and Gurd, 1984; Mighiu 
et al., 2013). 
Systemic glucose levels influence satiety and while hypoglycemia 
accelerates gastric emptying, glucagon has shown to induce delayed 
gastric emptying in animals and humans (Jonderko et al., 1989; Kawa-
moto et al., 1985; Xu and Chen, 2007). Moreover, even blood glucose 
changes within the normal postprandial range have a significant impact 
on gastric emptying in both normal subjects and patients with insulin- 
dependent diabetes mellitus (Schvarcz et al., 1997). This is relevant 
because gastric stasis is one of the premonitory symptoms reported by 
migraine patients (Aurora et al., 2007; Aurora et al., 2006; Parkman, 
2013) and might be involved in trigeminovascular nociceptive mecha-
nisms. Interestingly, antidopaminergic gastrointestinal prokinetic/ anti- 
emetic drugs that accelerate or “normalize” gastric emptying, such as 
domperidone and metoclopramide, have been co-administered with 
either triptans, paracetamol or nonsteroidal anti-inflammatory drugs 
(NSAIDs) as an effective abortive medication in the treatment of mi-
graines and cluster headaches, as they may speed up absorption of these 
antimigraine agents (De Ponti, 2000). Our efforts directed towards un-
derstanding the mechanism by which glucose changes influence trige-
minovascular neurons (Martins-Oliveira et al., 2017a) strengthen 
evidence favoring a role for glucagon in mediating migraine delayed 
gastric emptying. These observations raise many questions namely 
whether migraine patients skip meals due to delayed gastric emptying 
and perceived loss of appetite, which will be examined in detail below 
(6. Fasting/Skipping meals in migraine: voluntary or loss of appetite?). 
3.7. Leptin 
Leptin is a peptide secreted by the adipose tissue and circulating 
leptin is thought to be an indicator to the CNS of total body energy stores 
(Frederich et al., 1995). Leptin is transported to the brain where it 
crosses the blood–brain barrier (Friedman and Halaas, 1998; Weigle 
et al., 1997; Zhang et al., 1994) to act on the leptin receptor b (ObRb), 
the long form of the leptin receptor (Cohen et al., 2001; Elias et al., 1998; 
Myers et al., 2009; Scott et al., 2009; Tartaglia et al., 1995). Leptin ac-
tivates ObRb receptor in areas that have also been implicated in the 
pathophysiology of migraine (Akerman et al., 2011; Goadsby et al., 
2017), such as the brainstem, midbrain, hypothalamus, thalamus and 
cortex (Myers et al., 2009; Scott et al., 2009; Tartaglia et al., 1995). 
Furthermore, ObRb receptor mRNA is present in neuronal cell bodies of 
trigeminal motor nuclei (Grill et al., 2002). 
Leptin is the main anorexigenic peptide of feeding circuits. When 
injected either intravenously or i.c.v., leptin activates neurons in the 
PVN, ARC, VMH and DMH (Elias et al., 1998; Elmquist et al., 1997; 
Elmquist et al., 1998; Van Dijk et al., 1996), and suppresses feeding 
(Shiraishi et al., 2000). During fasting, serum levels of leptin decrease, 
normalizing after refeeding (Kolaczynski et al., 1996; Monteleone et al., 
2000). In the ARC, leptin targets POMC and AgRP/NPY neurons with 
opposing signaling effects: leptin activates the food suppressing POMC 
pathway (Schwartz et al., 1997), and actively inhibits the orexigenic 
AgRP/NPY pathway (Baskin et al., 1999b; Schwartz et al., 1996), and 
during fasting this effect is reversed. 
In order to modulate trigeminal nociceptive pathways, the endocrine 
system sends information to the central nervous system, suggesting that 
eventual perturbations of homeostatic feedback mechanisms can influ-
ence the activity of the trigeminovascular system. Indeed, there is evi-
dence of perturbations in leptin levels in migraineurs, with increased 
leptin and insulin levels in one study (Bernecker et al., 2010), but lower 
serum levels interictally in another (Guldiken et al., 2008). Furthermore, 
clinical studies report that the risk of chronic migraine is higher in obese 
migraineurs experiencing episodic migraines (Bigal et al., 2006; Bigal 
and Lipton, 2006), with attack frequency and severity increasing with 
body mass index (Bigal et al., 2006), and that morbidly obese women 
show a higher incidence of migraine with aura (Horev et al., 2005). 
Likewise, a higher migraine prevalence in metabolic syndrome patients 
was demonstrated comparing to the general population (Guldiken et al., 
2009). Given that the development of obesity is associated with leptin 
resistance (Caro et al., 1996; de Git et al., 2018) it seems plausible that a 
neuroendocrine pathway through leptin mechanisms might mediate a 
potential link between these metabolic conditions and migraine. In 
particular, migraine animal models have shown that obesity causes 
abnormal sensory processing within the trigeminovascular system 
(Rossi et al., 2013; Rossi et al., 2016) and diet-induced obesity results in 
trigeminal sensitization through CGRP mechanisms (Marics et al., 2016; 
Marics et al., 2017). We have recently shown that leptin exerts an 
antinociceptive action within the TCC (Martins-Oliveira et al., 2017a) 
and because obesity is characterized by reduced leptin sensitivity these 
data could shed light on possible mechanisms mediating the association 
of obesity with an increased frequency and intensity of migraine (Bigal 
et al., 2006; Bigal and Lipton, 2006; Bigal et al., 2007). Finally, the 
relative secretion of leptin and insulin correlates with body fat distri-
bution: insulin directly correlates with visceral fat, whereas leptin cor-
relates better with subcutaneous fat (Woods et al., 2003). Therefore, in 
order to dissect potential disturbances of leptin and insulin secretion in 
migraineurs comparing to controls, future studies should examine fat 
distribution in migraine patients (Gelaye et al., 2017), besides of using 
body mass index (BMI) as a method to diagnose overweight and obesity. 
Furthermore, leptin and orexins have common pathways within the 
hypothalamus, which highlight the potential synergistic leptin and 
orexinergic mechanisms in migraine pathophysiology. For example, LH 
ObRb neurons densely innervate and directly synapse with LH orexin 
neurons, and intra-LHA leptin treatment in Lepob/ob animals increased 
the expression of LH orexin mRNA expression (Louis et al., 2010). Evi-
dence shows that plasma orexin A levels correlate negatively and plasma 
leptin levels correlate positively with body mass index (BMI) (Adam 
et al., 2002), therefore, obese individuals should present lower plas-
matic orexin A levels and higher plasmatic leptin levels when compared 
to normal BMI individuals. This is in accordance with the lower pe-
ripheral orexin A levels seen in episodic migraineurs (Caproni et al., 
2011) and, also, with higher blood leptin levels shown in non-obese 
female migraineurs (Bernecker et al., 2010), comparing with healthy 
controls. 
Work from our laboratory, making use of a model of acute noci-
ceptive activation, where leptin levels were alleged to be physiologically 
normal, revealed that systemic leptin inhibits firing of dural-evoked 
trigeminovascular nociceptive neurons, and decreases the expression 
of the cell activation marker pERK in the TCC and hypothalamic ARC 
(Martins-Oliveira et al., 2017a). It should be noted, however, that leptin 
can exert different nociceptive effects depending on different models of 
pain, type of induced pain (acute vs chronic), site of administration of 
leptin and different basal levels of leptin expression (Hu et al., 2014; 
Kutlu et al., 2003; Li et al., 2013; Lim et al., 2009; Maeda et al., 2009; 
Wang et al., 2009; Watson et al., 2014), which should be considered for 
future experiments. 
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4. Understanding the orexigenic - anorexigenic circuit loop in 
trigeminovascular nociception 
NPY is a potent hypothalamic orexigenic peptide and evidence for 
the physiological role for NPY in energy homeostasis derives from 
studies showing the regulation of NPY gene expression in the hypotha-
lamic ARC by several peptides, and its release in the PVN (Kalra et al., 
1991). Conversely, insulin and leptin are considered adiposity signals, 
circulating at levels proportionate to body fat mass, and participate in 
the inhibitory regulation of both food intake and ARC NPY gene 
expression through a negative feedback signaling within the hypothal-
amus (Baskin et al., 1999a; Schwartz et al., 1992). It should be high-
lighted, however, that in contrast to ARC NPY, DMH NPY signaling also 
affects food intake but is not under the control of leptin (Bi et al., 2003). 
On the other hand, glucagon is not considered an adiposity signal, but is 
known to decrease food intake (Woods et al., 2006). 
It has been shown that insulin, leptin and glucagon inhibit TCC 
nociceptive activation in healthy animals (Martins-Oliveira et al., 
2017a) and because NPY has the opposite effect in food intake, one 
would expect NPY to have a pro-nociceptive action in the same animal 
model. Contrary to expectations, we have shown NPY reduced trige-
minovascular nociceptive activation through Y1 receptor (Martins-Oli-
veira et al., 2016). This could be explained by the fact that, despite the 
fact of opposing roles in food intake control, there is a tight regulation of 
these peptides with bidirectional feedback loops to ensure that these 
peptides can respond rapidly and for prolonged durations in various 
food-accessible conditions. For instance, when NPY is infused chroni-
cally into the brain of ad libitum-fed rats there is an increase in leptin 
expression in adipose tissue, in part, via NPY-induced hyper-
insulinaemia (Sainsbury et al., 1996). Because NPY administration in-
duces a negative feedback signaling from the adipose tissue and 
pancreas (Sainsbury et al., 1996), NPY can exert an indirect anti-
nociceptive action via leptin and insulin action in the TCC (Martins- 
Oliveira et al., 2017a). Moreover, acute i.c.v. NPY induces secretion of 
glucagon following fasting in in vivo animal experiments (Wilding et al., 
1995). Thus, it is likely that overlapping intracellular signaling path-
ways mediate the general response to these diverse metabolic signals. An 
integrated view of appetite-related peptides feedback loop is described 
in Fig. 2. 
On a different note, sleep disruptions have been implicated in 
metabolic dysregulation (Tsuneki et al., 2016), which may have physi-
ological significance in migraine given that disturbance of sleep habits is 
a commonly listed trigger (Fukui et al., 2008; Holland, 2014; Kim et al., 
2017). For instance, sleep deprivation induces an increase in glucose and 
insulin plasmatic levels (Reynolds et al., 2012) and lower glucose 
tolerance (Spiegel et al., 1999; Spiegel et al., 2005), as well as reduced 
leptin levels (Chaput et al., 2007; Spiegel et al., 2004a; Spiegel et al., 
2004b). A recent study in rodents has confirmed that even a short period 
(4 h) of sleep deprivation impairs glucose tolerance by attenuating the 
first-phase insulin response to a glucose load (Jha et al., 2016). Knowing 
that migraine patients respond differently to changes of the sleep/wake 
cycle (van Oosterhout et al., 2018), these data point to the possibility 
that the combination of fasting/ skipping meals with another perceived 
migraine trigger, such as sleep disturbances, is likely to disrupt the 
signaling pathways of any of the aforementioned peptides. An important 
point is that parallel anabolic and catabolic pathways are both tonically 
active and both influenced by adiposity signals. Overall, it seems plau-
sible that NPY might have a protective physiological role after fasting/ 
skipping meals, when its hypothalamic expression is increased, but this 
action could be compromised in migraineurs due to dysfunctional 
signaling or lower sensitivity to NPY, leptin, insulin or glucagon. 
Fig. 2. Feedback mechanisms of neuroen-
docrine appetite control and its inputs to 
modulate trigeminovascular antinociception. 
During fasting or food deprivation, NPY 
expression is upregulated in the hypotha-
lamic ARC (White and Kershaw, 1990; Xu 
et al., 1998). Activity of NPY is able to in-
fluence other peripheral peptides in order to 
maintain body-brain homeostasis. For 
example, when NPY is infused chronically 
into the brain of ad libitum-fed rats there is an 
increase in leptin expression in adipose tissue 
(Sainsbury et al., 1996) and basal insulin 
levels (Zarjevski et al., 1993). Acute i.c.v. 
NPY induces secretion of glucagon in fasted 
animals (Wilding et al., 1995). Conversely, 
NPY brain infusion can induce a negative 
feedback signaling from the adipose tissue 
and pancreas (Sainsbury et al., 1996). While 
central NPY influences peripheral insulin 
release pancreatic β-cells indirectly via 
parasympathetic pathways (Wisialowski 
et al., 2000), acute brain administration of 
insulin inhibited the fasting-related increase 
in ARC preproNPY mRNA levels (Schwartz 
et al., 1992; Sipols et al., 1995). Moreover, 
infusion of leptin in the brain inhibits the 
expression of NPY mRNA in the ARC in fas-
ted animals (Schwartz et al., 1996). There is 
also a functional crosstalk between the pancreas and the adipose tissue and within the pancreas itself. Systemic injection of glucagon stimulates insulin secretion in 
anaesthetized mice and isolated pancreas islets through a paracrine mechanism (Song et al., 2017) and acute administration of leptin improves glucose metabolism 
independent of elevations in insulin levels, suggesting an improvement of insulin sensitivity (Kamohara et al., 1997). In a migraine animal model, systemic 
administration of NPY, leptin, insulin and glucagon is able to inhibit in vivo trigeminovascular nociceptive firing, impacting hypothalamic and TCC cell activation as 
well as blood glucose levels (Martins-Oliveira et al., 2016; Martins-Oliveira et al., 2017a). These peptides have opposing roles in food intake, yet there is a tight 
regulation within body-brain feedback loops to maintain body homeostasis. We believe that disruption of the signaling pathways of any of these peptides is likely to 
disturb trigeminovascular signaling and contribute to altered feeding behavior in migraine. NPY, neuropeptide Y; i.v., intravenous; i.c.v., intracerebroventricular.   
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5. Glucose metabolism disturbances in migraine: the role of 
appetite-regulating peptides 
Increasing evidence shows that glucose metabolism is disturbed in 
migraine, as significant prevalence of insulin resistance has been 
observed in chronic migraine patients (Fava et al., 2013; Siva et al., 
2017). Moreover, headache is associated with high fasting glucose blood 
levels and migraine is specifically associated with higher insulin levels, 
after fasting and after the oral glucose tolerance test (Bernecker et al., 
2010; Cavestro et al., 2007; Rainero et al., 2005). Glucose metabolism 
has been studied in a migraine animal model showing that a potential 
neurobiological link between migraine and impaired metabolic ho-
meostasis may occur through disturbed glucose regulation or, on the 
contrary, that abnormal activation of the trigeminovascular system can 
deregulate blood glucose levels (Martins-Oliveira et al., 2017a). While 
hyperinsulinemia is an adaptive mechanism that enables the mainte-
nance of normoglycemia in the presence of insulin resistance (Wilcox, 
2005), the exact mechanisms responsible for these metabolic distur-
bances in the migrainous brain are yet to be fully understood. 
A study using the patients as their own controls (during an attack and 
in the attack-free period) reported an impaired tolerance to glucose as 
well as lower insulin levels during the migraine attack (Shaw et al., 
1977). This is in accordance with a report showing that insulin- 
deficiency is required for glucose intolerance (higher glycemic 
response) in response to hyperglucagonemia, comparing to normal 
controls (Sherwin et al., 1976). These data point to a primary role of 
insulin in impaired glucagon signaling, via dysfunctional or failure of 
negative feedback in glucose control. On the other side, it is known that 
glucagon is secreted during a meal, signaling the hypothalamus to 
reduce glucose levels. Because glucagon demonstrated antinociceptive 
effects in a migraine animal model (Martins-Oliveira et al., 2017a), this 
might explain why refeeding following food deprivation, with conse-
quent glucagon release, can be protective and abort or improve head-
ache in susceptible individuals. 
Following food intake, plasmatic glucose and insulin levels rise and 
combine to suppress glucagon secretion by the pancreatic α-cell (Gerich 
et al., 1976; Le Marchand and Piston, 2010) and this resultant drop in 
plasmatic glucagon levels contributes to the reduction in hepatic glucose 
production and to maintenance of normal glucose homeostasis. 
Migraine patients showed diminished sensitivity to the hyperglycaemic 
action of glucagon (De Silva et al., 1974) and this can be explained by 
chronically elevated glucose and insulin concentrations which lead to a 
reduction in basal hepatic glucose production. It is also possible that 
chronic fasting hyperglycemia and insulin oversecretion will interfere 
with normal insulin/glucagon ratio and physiological nociceptive 
modulation. 
Moreover, accurate sensing of insulin by hypothalamic insulin re-
ceptors is essential for an effective control of food intake, as well as 
normal control of hepatic glucose output. Convergent signals from in-
sulin and leptin act in the CNS to regulate both nociception and glucose 
homeostasis (Martins-Oliveira et al., 2017a) and a defect in either 
peptide signaling can result in appetite changes and/or insulin resis-
tance. It is noteworthy that acute administration of leptin in mice im-
proves glucose metabolism (glucose output and glucose uptake), 
independent of elevations in plasma insulin, improving insulin sensi-
tivity (Kamohara et al., 1997) (Fig. 2). However, clinical reports pro-
posing insulin resistance is present in migraine do not distinguish 
between peripheral or central insulin resistance. Nevertheless, since 
reduced leptin signaling can result in systemic and central insulin 
resistance (Ikeda et al., 1986; Zhang et al., 1994), this suggests that 
leptin signaling might be impaired in migraine patients. Conversely, 
clinical studies evaluating leptin levels in migraineurs have been 
inconclusive so far and have shown contradictory results (Guldiken 
et al., 2008; Pisanu et al., 2016; Rubino et al., 2016). This is likely due to 
substantial study design differences and conflicting results limiting 
definitive conclusions as reported in a recent systematic review (Peterlin 
et al., 2016). 
While the orexigenic functions of NPY signaling in CNS have been 
studied extensively in numerous species— both mammalian and non- 
mammalian, its energy regulation actions in the periphery are far less 
understood. Indeed, no effects have been described after peripheral 
infusion (Beck, 2006). Nonetheless, it is known that there is a close 
regulatory loop by which NPY and insulin control expression and 
function of each other. On one hand, central NPY influences peripheral 
insulin release pancreatic β-cells indirectly via parasympathetic path-
ways, followed by insulin action on hypothalamic NPY neurons to 
reduce NPY levels (Wisialowski et al., 2000). Additionally, chronic 
central NPY is known to cause increased basal levels of insulin (Zarjevski 
et al., 1993). On the other hand, acute elevation of insulin levels by 
direct administration into the brain was able to reduce ARC NPY levels 
(Schwartz et al., 1992; Sipols et al., 1995) (Fig. 2). The inhibitory tone 
by peripheral insulin is confirmed in a study using a diabetic rodent 
model of insulin deficiency and associated hyperglycemia, such as the 
streptozotocin rat, where NPY expression levels in the hypothalamus are 
strongly up-regulated (Gelling et al., 2006). In particular, the absence of 
insulin receptors signaling in NPY neurons also leads to a significant up- 
regulation of hypothalamic NPY expression (Loh et al., 2017). This 
suggests the development of resistance to the feedback effects of insulin 
on hypothalamic NPY in obesity and insulin resistant states, which are 
characterized by chronically elevated insulin levels (Könner and Brün-
ing, 2012). Recently, our group has shown that exogenous administra-
tion of NPY inhibits nociceptive trigeminal inputs in a healthy animal 
(Martins-Oliveira et al., 2016), however what is less known is the effect 
of NPY associated with deficient insulin signaling, as suggested in 
migraineurs, which challenges further studies in migraine animal 
models. 
It is important to address that acute changes of systemic glucose 
levels can alter TCC nociceptive responses, perhaps not directly, but by 
perturbation of the normal physiology and peptide secretion, i.e., 
perturbation of insulin, leptin and glucagon pathways – which conse-
quently regulates blood glucose levels. For instance, a study by Rajen-
dran et al. (Rajendran et al., 2001), showed that the pain threshold was 
modulated by insulin rather than blood glucose levels. This study 
demonstrated that high serum insulin levels exerted significant anti-
nociceptive effects, irrespective of hypo-, eu- and hyperglycemia con-
ditions. In addition, a rather small clinical study showed higher sucrose- 
induced serum insulin level in migraineurs comparing to controls, 
without development of sucrose-induced hypoglycemia (Kokavec and 
Crebbin, 2010). Thus, it is likely that insulin plays a predominant role 
through an overall direct action on nociception and indirect action on 
leptin and glucagon effects, through positive and negative feedback 
loops, respectively. 
Common forms of migraine are likely to be the result of several ge-
netic factors which interact with each other and with environmental 
influences that finally lead to an increase in the susceptibility of 
migraine (Goadsby et al., 2017). Genetic studies also suggest that 
migraine patients may have an increased vulnerability to altered 
metabolism(Gross et al., 2019b), especially glucose metabolism. Non- 
mitochondrial genetic evidence shows associations of migraine with 
polymorphisms in insulin receptor-related genes (McCarthy et al., 2001; 
Rainero et al., 2005) and the SLC2A1 gene which encodes the glucose 
transporter 1 (GLUT1) protein(Mohammad et al., 2014). The GLUT1 
deficiency syndrome, a condition of impaired brain glucose transport, 
has been linked to hemiplegic migraine and migraine with aura 
(Mohammad et al., 2014). Furthermore, mitochondrial genetic evi-
dence, including genes that encode nuclear-encoded mitochondrial 
proteins, suggest a generalized metabolic dysfunction in migraine, 
where suboptimal mitochondrial functioning together with an imbal-
ance between energy supply and demand may increase migraine sus-
ceptibility (Gross et al., 2019b). Given that mitochondria, vital 
organelles that provide cellular energy, play a pivotal role in insulin 
signaling(Cheng et al., 2010), it is likely that the suboptimal 
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mitochondrial functioning may lead to the impaired insulin sensitivity 
observed in migraine patients (Cavestro et al., 2007; Rainero et al., 
2005). 
6. Fasting and/or skipping meals in migraine: voluntary or loss 
of appetite? 
Brain systems interact to maintain energy homeostasis and the 
bidirectional interaction of feeding and sensory processing of pain has 
been specifically examined in a migraine animal model, where Malick 
and Burstein (2001) found that noxious stimulation of the dura mater in 
conscious rats induced a transient suppression of food intake, through 
activation of neuronal populations in the medullary dorsal horn areas, in 
parabrachial and hypothalamic neurons. Conversely, motor withdrawal 
responses to an acute painful stimulus are inhibited during feeding 
behavior, through the action of brainstem pain-modulatory neurons 
(Foo and Mason, 2005; Mason and Foo, 2009). More recent work, 
making use of genetically encoded optogenetic and pharmacogenetic 
tools showed that food deprivation-induced hunger selectively blocks 
inflammatory phase pain responses but has no effect during the acute 
phase response to chemical, thermal or mechanical pain (Alhadeff et al., 
2018). 
At this point, it is useful to highlight the notion that fasting is a 
conscious decision to skip meals, a voluntary action; whereas skipping 
meals refers to depriving oneself of food and it may occur without 
intention. Most of the literature in headache research use both terms 
interchangeably and regardless of the metabolic differences, we use 
fasting and/or skipping meals unless the original research study clearly 
states one or another. 
Skipping meals is one of the most consistent triggers reported by 
migraine patients and these studies bring our attention to the important 
fact that it is still unclear whether skipping meals is a cause or a 
consequence of abnormal nociceptive TCC activation in migraine. 
As a cause, food deprivation through voluntary abstention from food 
is exemplified by religious fasting, e.g. “Yom Kippur Headache” and 
“First of Ramadan Headache”. Clinically, the fasting headache is more 
likely to develop in patients with a history of headache and increases 
with the duration of the fast (Mosek and Korczyn, 1995), and inter-
mittent fast and fluid restriction increases the frequency of migraine 
attacks (Abu-Salameh et al., 2010). Evidence indicates that there is a 
small weight and fat mass loss during the month-long Ramadan, 
regained 4 weeks afterwards (Fahrial Syam et al., 2016; Hajek et al., 
2012; Norouzy et al., 2013) and a reduction on fasting blood glucose 
levels (Ibrahim et al., 2008; Kul et al., 2014). In healthy females, serum 
leptin levels progressively increase and NPY levels decrease throughout 
the month (Kassab et al., 2004; Kassab et al., 2003). Although the un-
derlying mechanism responsible for headache during religious fasting is 
unclear, there is evidence that shifting meal timing causes a comparable 
shift in plasma hormonal rhythm (Johnston, 2014). Perhaps this shift in 
circadian rhythm, in patients with headache history, has a central role in 
modulation of pain. It would be interesting to examine the variation of 
metabolic parameters (e.g. leptin, insulin and NPY) during religious 
fasting in headache patients. 
Note that voluntary abstention from food can indeed delay a meal, 
yet it is the unnoticed way of skipping meals caused by involuntary loss 
of appetite that we would like to bring attention to herein. Indeed, 
gastric motility may play a role in loss of appetite leading the unaware 
migraine patient to skip meals. Glucagon can induce increased post-
prandial satiety and delayed gastric emptying (Jonderko et al., 1989), 
which may have appetite-suppressing effects (Goyal et al., 2019). Of 
note, increased fasting glucagon levels and delayed glucagon suppres-
sion, together with increased circulating insulin levels, develop in par-
allel with insulin resistance (Færch et al., 2016). Given that insulin 
sensitivity is impaired in migraineurs (Bernecker et al., 2010; Cavestro 
et al., 2007; Fava et al., 2013; Rainero et al., 2005; Siva et al., 2017) and 
glucagon is able to inhibit TCC nociceptive activation in healthy animals 
(Martins-Oliveira et al., 2017a), it is possible that glucagon signaling is 
disrupted through insulin mechanisms. One study comparing fasting 
hepatic gluconeogenesis by administering glucagon in migraineurs and 
control subjects (De Silva et al., 1974) has shown that the maximal rise 
in blood glucose levels was lower in migraine patients, suggesting the 
normal hyperglycemic response might be impaired in these patients. 
These clinical studies and others (Martins-Oliveira et al., 2017a) suggest 
that glucagon signaling pathway might be impaired at the level of 
gluconeogenesis in the liver, as well as within the TCC, which can 
eventually cause glucagon oversecretion as part of a feedback mecha-
nism. Consistent with this view, abnormal glucagon signaling together 
with impaired insulin sensitivity would increase systemic glucose levels, 
thereby inducing delayed gastric emptying. This viewpoint is supported 
by the fact that migraine attacks have been linked to gastric stasis, with 
studies reporting slower gastric emptying during the attack as well as 
interictally (Aurora et al., 2007; Aurora et al., 2006; Aurora et al., 2013). 
Remarkably, abortion of the migraine attack is facilitated when acute 
migraine medication is administered together with gastroprokinetic 
medication (Volans, 1975; Volans, 1978). Fig. 3 describes a hypothetical 
explanation of environmental and sensory factors leading to fasting or 
skipping meals in migraine. 
Overall, the data suggests migraine attacks emerge due to a disorder 
of brain sensory processing that itself likely cycles, influenced by ge-
netics and the environment. Following CNS (central nervous system) 
disruption and activation of structures involved in homeostasis (e.g. 
hypothalamus, etc.), altered neuroendocrine signaling occurs leading to 
changes in satiety and metabolism (e.g. glucose metabolism). These will 
most likely impact feeding behavior - already part of the symptom-
atology of the ongoing attack yet creating the illusion of a trigger and 
misinterpreted by the patient. Whether metabolic and satiety imbal-
ances during the migraine episode are (undesirable) consequences of the 
migraine pathophysiology itself or rather contribute to restore brain 
energy homeostasis - as a protective, adaptive and temporary response 
to meet the cerebral energy needs - remains unknown (Goadsby et al., 
2017; Gross et al., 2019b; Martins-Oliveira et al., 2017a). 
A feature of the glucose metabolism includes the production of ke-
tone bodies through dietary ketosis which has been studied in several 
neurological diseases and has been associated with headache symptoms 
improvements (Augustin et al., 2018; Murano et al., 2021). Ketone 
bodies mediate several biological mechanisms namely glucose trans-
port, mitochondrial function, oxidative stress, neural excitability, neu-
roinflammation and the gut microbiota (Murano et al., 2021). Ketogenic 
diets act through a combination of mechanisms, which are linked to the 
effects of ketones and dietary glucose restriction, and to interactions 
with receptors, channels, and metabolic enzymes (Augustin et al., 
2018). Although the specific mechanisms of ketogenic diet therapy in 
migraine prevention are still uncertain, as well as other dietary ap-
proaches lacking evidence (Eigenbrodt et al., 2021), it has been pro-
posed that dietary ketosis restores brain metabolism and excitability 
(Gross et al., 2019b). This is supported by the positive outcome in a 
small, controlled trial of a ketogenic diet (Di Lorenzo et al., 2019). In 
preclinical models, the susceptibility to cortical spreading depression 
(CSD) - the animal correlate of the human aura - is strongly modulated 
by metabolism, namely hypoxia and cerebral glucose availability, and 
treatment with a middle chain triglyceride enriched ketogenic diet, as an 
alternative energy substrate to glucose, showed protective effects 
against CSD (reviewed in detail elsewhere (Gross et al., 2019a)). 
Moreover, dietary ketosis is effective in enhancing the sensitivity of the 
insulin receptor and improving glycemic control (Augustin et al., 2018). 
Given that dietary ketosis involves reduced carbohydrate ingestion, 
possible mechanisms for the metabolic health benefits in migraine pa-
tients may include glycemic stabilization (lower blood glucose levels 
and glycemic fluctuations) and improved systemic insulin sensitivity 
(reduced insulin secretion and thus reduced fluctuation of insulin 
levels). Taking into consideration the extensive metabolic effects of di-
etary ketosis and its metabolic parallelism with fasting, it is possible that 
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the loss of appetite (speculated in the pathophysiological model pre-
sented herein as a premonitory symptom indirectly through skipping 
meals) could be an adaptive form of compensation to restore the brain 
energy homeostasis. Based on available evidence, future studies 
including high-quality randomized controlled trial data on dietary 
ketosis are necessary to further specify the roles of components in ketone 
bodies and their putative therapeutic targets and related pathways in 
migraine patients. Given that human nutritional intervention studies are 
challenging to conduct and may impact future meta-analysis of effects, a 
few notes should be taken into consideration: the ketogenic diet causes 
ketosis and simulates the physiological state of fasting, yet not every 
low-carbohydrate diet is ketogenic and, thus, ketosis should be techni-
cally confirmed; the ketogenic diet comprises several sub-type diets 
(Kirkpatrick et al., 2019) and, hence, the detailed protocol should be 
fully disclosed; importantly, adherence to ketogenic diet is particularly 
challenging because it comprises a very limited number of allowed foods 
that will likely influence diet palatability and consequently the bio-
psychosocial profile of migraine patients. Thus, referral to a registered 
dietitian (RD) for medical nutrition therapy and lifestyle counseling in 
migraine is advisable (Kirkpatrick et al., 2019). 
7. Integration of contrasting feeding behaviors: skipping meals 
vs food craving 
The link between both feeding behaviors – skipping meals and food 
craving - is hard to reconcile due to the majority of the studies being 
retrospective and to the fact that only recently investigation of the 
premonitory phase of the migraine has expanded. Even though both may 
occur in the premonitory phase, migraine symptomatology associates 
with many inter-individual differences and, additionally, there are no 
data confirming both occur in the same individual and in the same 
phase. It is possible the same patient develops food cravings after skip-
ping meals, yet a cause-and-effect relationship is difficult to clarify with 
the current available scientific evidence. Neuronal fluctuations and 
functional reorganization of the brain throughout the migraine cycle 
may play a role. 
Given that natural fluctuations in neuronal excitability in the brain 
have been observed (Fox and Raichle, 2007) and sensitization is a 
fluctuating phenomenon, it is likely that the brain may be naturally 
protected at times of lower excitability, but much more sensitive at the 
peak of excitability fluctuations (Goadsby et al., 2017). Findings from 
brain imaging studies show that resting brainstem function fluctuates 
over the migraine cycle (Meylakh et al., 2021) along with functional 
reorganization of networks between subcortical structures involved in 
migraine pathophysiology, with distinct results throughout the migraine 
cycle, namely altered hypothalamic-brainstem connectivity (Karsan and 
Goadsby, 2018; Schulte and May, 2016). In addition, the ongoing al-
terations in connectivity between the pons and cortical regions continue 
to mediate non-painful symptoms, homeostatic dysregulation, etc. 
(Karsan et al., 2020a). These functional connectivity alterations suggest 
that there is altered subcortical-cortical network integrity in areas of the 
brain involved in homeostatic functions and some of these alterations 
continue into the headache phase. Given the central role of the hypo-
thalamus in appetite regulation, these connectivity alterations may ac-
count for the putative appetite changes reported by patients, i.e., it is 
possible that fluctuations in appetite and consequently feeding behavior 
occur in parallel with brain connectivity fluctuations. Nonetheless, to 
what extent appetite fluctuates in people with migraine compared to 
healthy individuals is currently unknown. 
Fig. 3. Potential mechanisms involved in fasting/ 
skipping meals in migraine. Fasting/ skipping meals 
can be mediated by either loss of appetite or voluntary 
abstention from food. The latter is known to cause 
headache e.g., “Yom Kippur Headache” (Abu-Salameh 
et al., 2010; Mosek and Korczyn, 1995). Importantly, 
loss of appetite can occur as a consequence of 
abnormal nociceptive TCC activation, gastroparesis or 
disrupted glucose metabolism –factors that have been 
described in the context of migraine in human and 
animal studies (Aurora et al., 2007; Aurora et al., 
2006; Aurora et al., 2013; Bernecker et al., 2010; 
Cavestro et al., 2007; Fava et al., 2013; Malick et al., 
2001; Rainero et al., 2005; Siva et al., 2017). More-
over, disturbed homeostasis, for instance induced by 
the self-reported perceived migraine triggers sleep 
disruption and “let-down stress” (Fukui et al., 2008; 
Goadsby et al., 2017; Holland, 2014; Kelman, 2007; 
Kim et al., 2017; Lipton et al., 2014; Park et al., 2016), 
impacts both glucose metabolism and appetite- 
regulating peptides, like insulin and leptin (Chaput 
et al., 2007; Jha et al., 2016; Reynolds et al., 2012; 
Spiegel et al., 1999; Spiegel et al., 2004a; Spiegel 
et al., 2004b; Spiegel et al., 2005; Tsuneki et al., 
2016). Appetite-regulating peptides are released by 
the hypothalamus (NPY), adipose tissue (leptin) and 
pancreas (glucagon, insulin) and can alter satiety 
through gastric motility and blood glucose regulation. 
Given that gastric motility is a key mediator of hun-
ger/satiety and gastric stasis is able to induce loss of 
appetite (Janssen et al., 2011), it is possible that 
gastroparesis observed in migraine patients leads the 
patient to skip meals. The fact that exogenous 
administration of appetite- and glucose-regulating 
peptides modulates trigeminovascular nociceptive 
activation (Martins-Oliveira et al., 2016; Martins-Oliveira et al., 2017a), highlights the importance of metabolic pathways in migraine.   
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8. Key messages and the way forward 
In this review, we emphasized the substantial overlap between 
feeding behavior, energy metabolism and migraine. The fact that spe-
cific neuronal populations govern appetite and play a role in migraine 
pathophysiology is relevant because unlocking this overlap of neural 
networks will help determine locations (and its pharmacology) with 
which to target for migraine therapy. The data points to an improvement 
of the knowledge of appetite neurobiology by using migraine animal 
models that builds up on clinical studies. However, many fundamental 
questions remain unanswered, which raises new challenges for future 
research. 
An important first step is to pursue the potential behavioral rele-
vance of earlier cellular and in vivo observations (Martins-Oliveira et al., 
2016; Martins-Oliveira et al., 2017a), i.e. future studies must be able to 
use conscious migraine animal models and should explore alterations of 
feeding schedules, using feeding behavioral paradigms. It would be 
noteworthy to test the cumulative effects of food deprivation and other 
premonitory symptoms, such as yawning, photophobia, sleep distur-
bances, allodynia, stress and/or anxiety by using more complex para-
digms. Likewise, using obesity animal models is a valid way to test the 
effect of specific appetite-related peptides as it has been demonstrated 
the existence of an abnormal sensory processing within the trigemino-
vascular system in both high fat diet and leptin deficient mouse models 
of obesity (Rossi et al., 2013; Rossi et al., 2016). 
Another challenge is to improve characterization of food craving 
symptoms by improving accuracy of data collection in clinical neuro-
science studies (Taylor, 2019). A better characterization of the pre-
monitory phase of a migraine attack in terms of feeding behavior could 
give clues to study and define neural maps of circuits and signaling 
molecules, and eventually could make it possible to design drugs to 
tackle the migraine attack at its very earliest stages. Migraine patients 
report food cravings (Giffin et al., 2003b; Karsan et al., 2021; Schulte 
et al., 2015), yet what is less clear is whether these patients effectively 
ingest the craved food, whether it is in a compulsive overeating manner 
or whether it is after skipping a meal. Answering each of these three 
discrete questions will implicate different neurobiological mechanisms 
and thus detail-oriented questions will definitely direct research to more 
exciting breakthroughs. 
An observation worth noting is that the reporting frequency of un-
comfortable and hurting non-headache symptoms (e.g. photophobia, 
phonophobia, nausea, vomiting, stiff neck, difficulty concentrating and 
irritability) is higher than food craving in the premonitory phase 
(Drummond and Lance, 1984b; Giffin et al., 2003b; Schoonman et al., 
2006; Schulte et al., 2015). It is assumed that retrospective studies are 
open to recall bias and that the most severe symptoms may be selectively 
recalled and other may be forgotten (Giffin et al., 2016). Interestingly, a 
suboptimal recognition of premonitory symptoms during spontaneous 
attacks, or conversely over-reporting during the triggered attack, has 
been highlighted by a recent study (Karsan et al., 2020b) comparing 
triggered attacks (data acquired prospectively) to spontaneous attacks 
(retrospective recall). For instance, photophobia was more commonly 
triggered by nitroglycerin than reported spontaneously. This may be 
explained by the fact that a patient would notice photophobia more in a 
bright hospital room where the subject has little else to concentrate on 
and is asked specifically about it. In line with these observations, it is 
possible patients will be more likely to remember and report aversive 
and painful symptoms rather than appetitive symptoms like pleasurable 
cravings for chocolate, “salty fatty” foods, sugary drinks or sex, because 
the perception of pain is heightened. 
On the other hand, common and nonspecific nonheadache symptoms 
such as yawning, food craving, and fatigue are also experienced on a 
day-to-day basis by the general population (i.e. not suffering from 
migraine). For example, a recent study using glyceryl trinitrate (GTN) as 
a trigger (Onderwater et al., 2020) showed that craving for sweets was 
not significantly different between GTN responders and healthy 
controls, as opposed to nausea that was a specific symptom in GTN re-
sponders for an impending GTN-induced migraine-like headache, 
though it is debatable the occurrence of craving for sweets while the 
patient feels nauseous. 
Food craving may not be a specific early warning signal for the onset 
of migraine, but we believe it is meaningful and, in our experience, when 
assessing a patient it is essential to inform that specific premonitory 
symptoms can be associated with appetitive behavior so that in 
following migraine attacks the patient is aware and recognizes it, lead-
ing to a better understanding of its own attack and likeliness to report it. 
Furthermore, the study of hard-wired neural circuits mediating 
competing motivational states, such as pain, hunger, thirst, fear or social 
interaction, has gained momentum with several reports demonstrating 
prioritization of behavior (Alhadeff et al., 2018; Burnett et al., 2016; 
Essner et al., 2017). Interestingly, hunger/food craving persists 
throughout the headache pain phase (Giffin et al., 2003a) and is a 
frequently reported true postdrome symptom in adults and children with 
migraine (Giffin et al., 2003a; Giffin et al., 2016; Mamouri et al., 2018). 
A disorder is a disturbance of the normal homeostasis (Goadsby 
et al., 2017) and it is becoming clear that mechanisms regulating 
appetite and thirst homeostasis, as well as hedonic hunger, are 
compromised in migraine (Martins-Oliveira et al., 2016; Martins- 
Oliveira et al., 2017a). These neuropeptides potentially involved in 
feeding-related premonitory symptoms may make attractive therapeutic 
targets and developing mechanism-based therapies could tackle the 
desirable need to treat migraine patients with migraine medicines, i.e. 
developed specifically for migraine (Goadsby, 2016). Based on studies 
reported herein, several neuropeptides emerge as powerful and prom-
ising key targets in the prophylactic and acute treatment of migraine 
(Ong et al., 2018) and potentially co-morbidities related to eating dis-
orders and insulin sensitivity. For example, the highly anticipated hu-
manized CGRP monoclonal antibodies are the first mechanism-specific 
class of migraine preventive medications. In addition, clinical efficacy of 
drugs targeting PACAP or its receptors is gaining momentum and a 
Phase II clinical trial assessing the efficacy and safety of a monoclonal 
antibody against the PAC1 receptor is ongoing (NCT03238781) (Ong 
et al., 2018). Moreover, following disappointing studies with dual orexin 
receptor antagonists due to sleep-related side effects, interest still re-
mains in single orexin receptor antagonists. Other promising key re-
ceptor targets, such as the NPY Y1, leptin, insulin and glucagon, remain 
to be fully characterized in the context of migraine drug design and 
development. Furthermore, targeting these neuropeptides for drug 
development should consider potential adverse effects due to their 
involvement in several homeostatic control mechanisms other than 
feeding behavior. 
So what to answer to the burning question “Was it something I ate?”? 
The take-home message is that certain lifestyle modifications, such as 
specific dietary restrictions, are not evidence-based recommendations to 
treat or prevent migraine due to lack of randomized clinical trials. In 
addition, consistent with evolving literature, skipping meals may not be 
interpreted as a (perceived) trigger of migraine by patients, but rather 
likely to be an early premonitory manifestation. 
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Jancsó, G., Dux, M., 2016. Diet-induced obesity alters dural CGRP release and 
potentiates TRPA1-mediated trigeminovascular responses. Cephalalgia. 
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Tajti, J., Uddman, R., Möller, S., Sundler, F., Edvinsson, L., 1999. Messenger molecules 
and receptor mRNA in the human trigeminal ganglion. J. Auton. Nerv. Syst. 76, 
176–183. 
Tannenbaum, G.S., Goltzman, D., 1985. Calcitonin gene-related peptide mimics 
calcitonin actions in brain on growth hormone release and feeding. Endocrinology 
116, 2685–2687. 
Tartaglia, L.A., Dembski, M., Weng, X., Deng, N., Culpepper, J., Devos, R., Richards, G.J., 
Campfield, L.A., Clark, F.T., Deeds, J., Muir, C., Sanker, S., Moriarty, A., Moore, K.J., 
Smutko, J.S., Mays, G.G., Wool, E.A., Monroe, C.A., Tepper, R.I., 1995. Identification 
and expression cloning of a leptin receptor. OB-R. Cell. 83, 1263–1271. 
Taylor, F.R., 2008. Weight change associated with the use of migraine-preventive 
medications. Clin. Ther. 30, 1069–1080. 
Taylor, M., 2019. A review of food craving measures. Eat. Behav. 32, 101–110. 
Tkacs, N.C., Pan, Y., Sawhney, G., Mann, G.L., Morrison, A.R., 2007. Hypoglycemia 
activates arousal-related neurons and increases wake time in adult rats. Physiol. 
Behav. 91, 240–249. 
Tso, A.R., Goadsby, P.J., 2017. Anti-CGRP monoclonal antibodies: the next era of 
migraine prevention? Curr. Treat. Options Neurol. 19, 27. 
Tsuneki, H., Sasaoka, T., Sakurai, T., 2016. Sleep control, GPCRs, and glucose 
metabolism. Trends Endocrinol. Metab. 27, 633–642. 
Tuka, B., Helyes, Z., Markovics, A., Bagoly, T., Szolcsányi, J., Szabó, N., Tóth, E., 
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